JIMT-1  Xenografts

 

Rincon Bio performs JIMT-1 xenograft models to test efficacy of preclinical therapies.  Please see below for additional information or to request a quote. 

Breast

JIMT-1 is a carcinoma cell line (designated JIMT-1) from a pleural metastasis of a 62-year old patient with breast cancer who was clinically resistant to trastuzumab. Ref

Oncogene

JIMT-1 cells have an amplified HER-2 oncogene.  They overexpress HER-2 mRNA and protein, and the levels of HER-1, HER-3, and HER-4 mRNA and protein are similar to the trastuzumab-sensitive cell line SKBR-3.  The cell line lacks expression of hormone receptors (estrogen receptors and progesterone receptors) and is phenotypically of epithelial progenitor cell origin. JIMT-1 cells are insensitive to trastuzumab and another HER-2-inhibiting drug, pertuzumab (2C4), in vitro and in xenograft tumors. Ref

in vivo

Forms tumors in nude mice

Used in xenografts to test the efficacy of novel cancer therapeutics 

Request Quote

Receive a quote within one business day

Rincon Bio Growth Curve

jimt1.png

Cell Line: JIMT1

Mouse Strain: NOD.CB17 Prkdc<Scid>NCrHsd from Envigo

Gender: Female

Positive Control: Kadcyla

Concentration: 2.5mg/kg, 5mg/kg

Matrigel: Yes

Dosing: One dose, tail vein

From implant to stratification: 20 days

Cells Implanted per Animal: 5 million

WHY WORK WITH

RINCON BIO?

DOMESTIC QUALITY at COMPETITIVE PRICES

 

When you work with Rincon Bio, rest assured that all cancer efficacy studies will be performed in the USA, at competitive prices

SPEED TO INITIATION
 

Most efficacy studies can be initiated within two business days.

PERSONAL TOUCH

 

We love our clients!  We are easy to work with.  And we take a personal interest in our clients and their studies.